Medical/Pharmaceuticals
Updated Data from Phase II Clinical Trial of Iruplinalkib Tablets (Qixinke®) Presented at World Conference on Lung Cancer 2024
JINAN, China, Sept. 10, 2024 /PRNewswire/ -- During the World Conference on Lung Cancer (WCLC) held fromSeptember 7-10, 2024, in San Diego, California, updated findings from the Phase II clinical trial (INTELLECT study) were presented. The study assessed the efficacy and safety of Qilu Pharmaceut...
2024-09-10 18:00
1569
The 2024 International (Bozhou) TCM Expo Kicked Off
BOZHOU, China, Sept. 10, 2024 /PRNewswire/ -- On the morning of September 9, the 2024 International (Bozhou) TCM Expo and the 40th National (Bozhou) TCM Trade Fair officially kicked off in Bozhou,Anhui Province. In recent years, Bozhou has been enhancing mechanisms for the inheritance, innovatio...
2024-09-10 17:55
1306
Bambusa Therapeutics Inc. Announces Successful Series Seed Funding to Advance Innovative Bispecific Antibodies for Immunology & Inflammation
BOSTON, Sept. 9, 2024 /PRNewswire/ -- Bambusa Therapeutics Inc., a biotechnology company focused on developing bispecific antibodies for the treatment of immunological and inflammatory (I&I) disorders, announced the successful closing of its Series Seed financing round, raising approximately$15 ...
2024-09-09 21:09
1886
Lunit Joins Roche's Digital Pathology Open Environment to Advance Cancer Biomarker Testing
* Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pathology platform to enhance precision medicine and improve cancer biomarker testing SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solution...
2024-09-09 21:00
2144
Neurophet-NTU Singapore, recognized for outstanding joint research
- Neurophet accelerates global expansion for research and partnership in AI-driven brain image analysis SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced that Neurophet and NTU (Nanyang Technological Univers...
2024-09-09 21:00
2181
GenAssist Ltd Announced the First DMD Patient Dosed with its Base Editing Drug
SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- On September 06, 2024, GenAssist Ltd (GenAssist), announced the first DMD patient dosed with its base editing drug, GEN6050X injection, in an investigator-initiated trial (IIT). "This is the first-in-human trial for DMD gene editing therapy. It marks t...
2024-09-09 21:00
1644
MGI Launches New Nanopore Sequencing Products with Advanced CycloneSEQ Technology
SHENZHEN, China, Sept. 9, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today announced the global rights to commercialize and distribute the new sequencing products CycloneSEQ-WT02* and CycloneS...
2024-09-09 16:24
1971
Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization
TAIPEI, Sept. 9, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment tothe United States of its new ophthalmic drug, Clobetasol Propionate Ophthalmic Suspension, 0.05% (APP13007), manufactured by Bora P...
2024-09-09 15:00
2041
Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress
* The study involved end-stage oncology patients with no other suitable treatment options. * In this Phase Ib study, Pidnarulex (CX-5461) demonstrated acceptable clinical tolerability and showed preliminary signs of efficacy, even in patients who had previously failed treatment with PARP inhi...
2024-09-09 10:33
2050
Antennova to Present Latest Data of ATN-037 in a Mini Oral Presentation at ESMO Congress 2024
BOSTON, Sept. 8, 2024 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced thatit will present the latest data of CD73 small molecule inhibitor ATN-037 in a Mini Oral presentation at the 2024 European Society of Medical Oncology Congress (ESMO Congress 2...
2024-09-09 08:30
1680
Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024
HONG KONG, Sept. 8, 2024 /PRNewswire/ -- Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, either as a monotherapy or in combination with chemotherapy, for the perioperative treatment of ...
2024-09-09 02:17
1987
Bc Babycare Marks a Stellar Debut at Germany's Kind+Jugend 2024
COLOGNE, Germany, Sept. 6, 2024 /PRNewswire/ -- Bc Babycare, a leader in innovative products for mothers and babies, made a remarkable debut at Kind+Jugend 2024, the premier international trade fair for baby and toddler outfitting, which opened inCologne, Germany, on September 3. The brand capti...
2024-09-06 23:22
2833
Akeso to Present Data from 13 Clinical Studies at ESMO 2024, Featuring its Internally Developed Cadonilimab, Ivonescimab, Ligufalimab, and other I/O Antibodies
HONG KONG, Sept. 5, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) will showcase promising results from 13 clinical studies on its internally developed PD-1/CTLA-4 bispecific antibody cadonilimab, PD-1/VEGF bispecific antibody ivonescimab, next-generation CD47 monoclonal antibody ligufalimab, and co...
2024-09-06 08:54
2088
Baird Medical and ExcelFin Acquisition Corp Announce Effectiveness of Registration Statement
FORT MILL, S.C., Sept. 5, 2024 /PRNewswire/ -- Betters Medical Investment
Holdings Limited ("Baird Medical" or the "Company"), a leading microwave
ablation ("MWA") medical device developer and provider inChina, and ExcelFin
Acquisition Corp. ("ExcelFin") (NASDAQ:XFIN
2024-09-06 05:23
3641
A Small Step towards a Big Mission! World's First! UltraDx Received First Clinical Approval of Single-Molecule Analyzer, in China
SHANGHAI, Sept. 5, 2024 /PRNewswire/ -- UltraDx Bio is proud to announce that its flagship product, the UD-X™ Fully Automated Single-Molecule Array Fluorescence Immunoassay Analyzer, has received its first clinical registration approval inChina. This groundbreaking achievement is now officially l...
2024-09-05 20:35
2509
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation
* Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with bioengineered human mini-heart drug discovery and screening technology platforms * Transactio...
2024-09-05 20:00
3154
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration
NANJING, China, Sept. 5, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U....
2024-09-05 13:49
2048
Grand launch | Sanyou Bio monkeypox antibody made a great breakthrough
SHANGHAI, Sept. 4, 2024 /PRNewswire/ -- On August 28, 2024, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced the launch of 65 kinds of monkeypox antibodies, antigens and cell lines, which has won wide praise from the public. Monkeypox human antibody, as the core product launched by Sanyo...
2024-09-05 08:00
1547
LakeShore Biopharma Announces Leadership Transitions
GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...
2024-09-04 20:00
1983
HKBU develops Chinese medicine for ulcerative colitis approved by National Medical Products Administration for clinical trial
HONG KONG, Sept. 4, 2024 /PRNewswire/ -- The Centre for Chinese Herbal Medicine Drug Development (CDD) at Hong KongBaptist University (HKBU) has achieved a significant milestone in developing a novel Chinese herbal formulation for ulcerative colitis remission maintenance. Following a submission o...
2024-09-04 15:13
2178
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 318 media titles]
2026-01-23 11:03
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 308 media titles]
2026-01-27 13:00
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 306 media titles]
2026-01-23 09:00Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 292 media titles]
2026-01-27 18:00
